Symbol
| USP9X
| contributors: mct - updated : 05-09-2019
|
HGNC name
| ubiquitin specific peptidase 9, X-linked
|
HGNC id
| 12632
|
Other morbid association(s)
|
Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
---|
tumoral
|  
|  
| --over
|  
|
increased expression in follicular lymphomas and diffuse large B-cell lymphomas correlates with increased MCL1 expression and poor prognosis | tumoral
|  
|  
|  
| loss of function
|
inactivated in over 50p100 of the pancreatic ductal adenocarcinoma (PDA) | constitutional
|  
|  
| --low
|  
|
lower levels of cytosolic USP9X and deubiquitinase activity in alpha-synucleinopathies may contribute to the accumulation and aggregation SNCA in Lewy bodies | constitutional
|  
|  
|  
| loss of function
|
resulted in changes to the neuronal cytoskeleton | constitutional
| germinal mutation
|  
|  
|  
|
associated with nonsyndromic X-linked intellectual disability | |
Variant & Polymorphism
|
| |
Candidate gene
Marker
| marker prognostic in follicular lymphomas and diffuse large B-cell lymphomas | Therapy target
|
System | Type | Disorder | Pubmed |
cancer | reproductive | prostate | |
targeting the USP9X/PBX1 axis could be a potential therapeutic strategy for managing advanced prostate cancer | cancer | hemopathy | | |
therapy target in follicular lymphomas and diffuse large B-cell lymphomas |
| | |